What improvements have been seen in patients given lamivudine (3TC) for the treatment of hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Histologic improvement (ie, reduction of the histologic activity index by >2 points) has been noticed in approximately 50% of patients taking 3TC. The adverse effects are negligible, although a transient elevation of aminotransferases can be noticed shortly after starting treatment.

Treatment with 3TC has also been shown to dramatically improve the condition of patients with decompensated disease due to HBV reactivation. Patients with HIV infection and fulminant hepatic failure due to active HBV infection may receive 3TC-only treatment. [42] Those with HIV/HBV coinfection who are eligible for antiretroviral therapy and have less severe hepatic injury should defer the antiretroviral treatment until resolution of the liver injury. [42]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!